Social Media Influencers Fueling Parallel Trade for Unapproved Weight-Loss Drug

A shadow market for unlicensed weight-loss medications is being driven by TikTok fitness influencers and sellers on communication apps, based on new investigations.

Experimental Treatment Gaining Traction Online

Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing effects. Viewers are encouraged to contact these profiles directly for supplier links, while also receiving promotional offers.

Active Commerce on Social Networks

Additionally, a flourishing market exists on messaging services, where groups with thousands of members share “before and after” images, injection guides and claims of next-day UK delivery. Vendors market the drug there before directing buyers to WhatsApp for purchases.

Understanding Retatrutide

Retatrutide is an investigational injection created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies indicate it could help patients lose up to 25% of their total weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Professionals Express Concerns

However, doctors and pharmacists have cautions that the distribution of what remains an unlicensed drug in the United Kingdom is worrisome and could result in users injecting substances of uncertain source.

Some experts said the demand for retatrutide could be connected to the increasing price of licensed weight loss products such as Mounjaro.

Regulatory Status and Enforcement

Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that must not be marketed or supplied for human use under the British medical regulations.

Several influencers attempt to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach medicines, marketing, and consumer laws, potentially leading to fines, legal action or imprisonment.

Service Reaction and Content Elimination

Based on the social media company, the service has taken down violative content and banned associated keywords and search suggestions. The organization said it was dedicated to keeping the service secure and investing in strengthening compliance measures.

Digital Marketplace Activities

Investigations also found groups with up to 9,000 participants marketing the experimental drug using Telegram's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly displays channels with numerous of users, filled with images of weight loss, positive testimonials and step-by-step guides for mixing or administering at home.

Within minutes of entering one community, a seller shared contact information, where most transactions take place. The vendor sent an instruction manual and promised shipping within 48 hours. When questioned whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about body mass, medical conditions or previous experience.

Product Details and Costs

Inside these groups, messages display black plastic parcels with Royal Mail labels, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, prepared at home with purified liquid, or pre-filled pens typically priced at £160 for 20 milligrams. When questioned how long a pen should be used, sellers give contradictory answers ranging from a several days to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for Telegram said it actively monitored dangerous material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“Individuals are injecting substances they cannot confirm. Even if the science behind retatrutide is sound, these digital products may not include what they claim,” said Jason Murphy, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current price rises for authorized weight-loss medications such as Mounjaro. “With prices rising, patients are turning to social media. But fake injections are highly risky. You cannot know what’s contained or whether the environment they were produced in was clean,” she explained.

Her staff has previously seen patients injured by self-injection from unconfirmed suppliers. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” stated the doctor. “These substances could be contaminated or improperly measured.”

Producer Statement

A representative from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they said, noting that any product “misleadingly claiming itself as a company investigational product not yet approved … may subject patients to possibly serious health risks”.